Drug Cocktail

Phase 1Small molecule

Eli Lilly

Drug Cocktail is one of 104 small molecule programs targeting Metastatic Melanoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic MelanomaActive, not recruiting

Prostate CancerActive, not recruiting

PsoriasisActive, not recruiting

Prostatic Neoplasms, Castration-ResistantActive, not recruiting

Metastatic MelanomaPhase 1

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

PsoriasisPhase 1

Active, not recruiting

Prostatic Neoplasms, Castration-ResistantPhase 1

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Drug Cocktail

Eli Lilly

Phase 1

7 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Osmitrol

BB. Braun Medical Inc.

Preclinical

—10

Ifex

BBaxter Healthcare Corporation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT02592317

Clinical

Trials by Indication[1]

Psoriasis2 trials

A Study of Mirikizumab in Participants With Plaque Psoriasis

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT03718884·29 enrolled

A Study of Ixekizumab in Participants With Plaque Psoriasis

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02993471·28 enrolled

Abemaciclib1 trial

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02688088·48 enrolled

Metastatic Melanoma1 trial

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Completed· Roche logo

Roche·Phase 1·NCT01001299·25 enrolled

Drug Interactions1 trial

Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach

Recruiting·WWashington State University·Phase 1·NCT06693960·16 enrolled

Drug1 trial

Effects of Repeated Doses of Foliglurax on Drug Metabolizing Enzymes in Healthy Subjects

Completed· Lundbeck logo

Lundbeck·Phase 1·NCT04275115·20 enrolled

1 more indication

Prostatic Neoplasms, Castration-Resistant1 trial

Drug-drug Interaction Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Subjects With Castration-Resistant Prostate Cancer

Active, not recruiting·AAragon Pharmaceuticals, Inc.·Phase 1·NCT02592317·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Drug Cocktail. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drug Cocktail compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drug Cocktail. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eli Lilly

Drug Cocktail

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Psoriasis2 trials

Abemaciclib1 trial

Metastatic Melanoma1 trial

Drug Interactions1 trial

Drug1 trial

Prostatic Neoplasms, Castration-Resistant1 trial

References

Drug Info

Quick Facts

Related News